Christophe Weber, Takeda CEO (Shoko Takayasu/Bloomberg via Getty Images)

Take­da wins FDA ap­proval for self-ad­min­is­tered, sub­cu­ta­neous En­tyvio in ul­cer­a­tive col­i­tis

The FDA has ap­proved a sub­cu­ta­neous ver­sion of Take­da’s ul­cer­a­tive col­i­tis drug En­tyvio, more than three years af­ter re­ject­ing the com­pa­ny’s ap­pli­ca­tion over what it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.